Lamattina John L's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Mar 31, 2026
- Accession no.
- 0002001011-26-000036
- Filed
- Mar 31, 2026
- Trade date
- Mar 6, 2026
- Filing delay
- 25 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $433.8K. It was filed 25 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lamattina John LCIK 0001216074 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | Common Stock | MOption exerciseAcquired | +2,161 | $114.15 | +$246,678.15 | 32,885 | Direct | |
| Mar 6, 2026 | Common Stock | SSaleDisposed | −2,161 | $200.76 | −$433,842.36 | 30,724 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | Common Stock | MOption exerciseDisposed | −2,161 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.